Twist Bioscience Corp (TWST)
29.15
+1.19 (+4.26%)
USD |
NASDAQ |
Jan 27, 16:00
29.24
+0.09 (+0.31%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.651B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -43.22% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.740 |
| Price to Book Value | 2.092 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
PR Newswire
01/27 22:50
PR Newswire
01/27 16:18
PR Newswire
01/27 05:45
Globe Newswire
01/26 11:00
Yahoo
01/26 08:00
PR Newswire
01/26 05:45
Accesswire
01/25 20:45
Globe Newswire
01/25 12:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/03/2023 | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/03/2023 | -- | Results | Q1 2023 | -- | -- | -- | |
| 11/18/2022 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/18/2022 | -- | Results | Q4 2022 | -1.01 | -1.14 | 10.91% | |
| 08/05/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/05/2022 | -- | Results | Q3 2022 | -1.08 | -1.31 | 17.40% | |
| 05/05/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q2 2022 | -1.02 | -1.30 | 21.57% |
*Estimated Date/Time
Earnings
Profile
Edit
| Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States. |
| URL | https://www.twistbioscience.com |
| Investor Relations URL | https://investors.twistbioscience.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 03, 2023 |
| Last Earnings Release | Nov. 18, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
| Revenue (TTM) | 203.56M |
| Total Expenses (TTM) | 452.58M |
| Net Income (TTM) | -217.86M |
| Total Assets (Quarterly) | 961.38M |
| Total Liabilities (Quarterly) | 171.99M |
| Shareholders Equity (Quarterly) | 789.38M |
| Cash from Operations (TTM) | -124.38M |
| Cash from Investing (TTM) | -232.93M |
| Cash from Financing (TTM) | 270.53M |
Ratings
Profile
Edit
| Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States. |
| URL | https://www.twistbioscience.com |
| Investor Relations URL | https://investors.twistbioscience.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 03, 2023 |
| Last Earnings Release | Nov. 18, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| TWST Tweets |